Developing new agents for treatment of childhood cancer: Challenges and opportunities for preclinical testing

Research output: Contribution to journalArticlepeer-review


Developing new therapeutics for the treatment of childhood cancer has challenges not usually associated with adult malignancies. Firstly, childhood cancer is rare, with approximately 12,500 new diagnoses annually in the U.S. in children 18 years or younger. With current multimodality treatments, the 5-year event-free survival exceeds 80%, and 70% of patients achieve long-term “cure”, hence the overall number of patients eligible for experimental drugs is small. Childhood cancer comprises many disease entities, the most frequent being acute lymphoblastic leukemias (25% of cancers) and brain tumors (21%), and each of these comprises multiple molecular subtypes. Hence, the numbers of diagnoses even for the more frequently occurring cancers of childhood are small, and undertaking clinical trials remains a significant challenge. Consequently, development of preclinical models that accurately represent each molecular entity can be valuable in identifying those agents or combinations that warrant clinical evaluation. Further, new regulations under the Research to Accelerate Cures and Equity for Children Act (RACE For Children Act) will change the way in which drugs are developed. Here, we will consider some of the limitations of preclinical models and consider approaches that may improve their ability to translate therapy to clinical trial more accurately.

Original languageEnglish (US)
Article number1504
JournalJournal of Clinical Medicine
Issue number7
StatePublished - Apr 1 2021


  • Drug development
  • Patient-derived xenografts
  • Pediatric cancer
  • Single mouse design

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Developing new agents for treatment of childhood cancer: Challenges and opportunities for preclinical testing'. Together they form a unique fingerprint.

Cite this